donepezil

(redirected from Aricept)
Also found in: Medical.
Related to Aricept: Namenda

do·nep·e·zil

 (dō-nĕp′ə-zĭl′)
n.
A drug, C24H29NO3, that inhibits acetylcholinesterase and is used in its hydrochloride form to treat mild to moderate dementia caused by Alzheimer's disease.

[Perhaps (in)done, a ketone (ind(ene) + -one) + (pi)pe(ridine) + alteration of (ben)zyl.]
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

donepezil

(dəˈnɛpəzɪl)
n
a drug used to treat dementia
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
Translations

donepezil

n donepezilo
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
regulatory approval to sell a higher dosage version of its best selling Alzheimer drug Aricept. The Food and Drug Administration on July 23 approved the 23-milligram once-daily Aricept tablet for Alzheimer.
Researchers found that of 3,536 nursing home residents, age 65, and older who took cholinesterase inhibitors such as donepezil (Aricept) and tacrine (Cognex) for dementia, the 376 who also took anticholinergics such as oxybutynin (Ditropan) or tolterodine (Detrol) for incontinence had a 50% faster decline in their ability to perform basic activities, such as dressing or bathing.
EISAI CO., maker of Aricept, the world's best-selling drug for Alzheimer's disease, said it will stop the development of its experimental Parkinson's disease treatment.
* Alzheimer's disease is incurable, although drugs such as Aricept can help control the symptoms.
Tokyo, Japan, Sept 3, 2005 - (JCNN) - Eisai announced on September 1 that its US subsidiary Eisai Medical Research has filed a supplemental New Drug Application (sNDA) for ARICEPT (donepezil HC1 tablet) with the U.S.
The medicines at the centre of the row - Aricept, Exelon and Reminyl - cost pounds 2.50 a day.
The three available, Aricept, Reminyl and Exelon, work by slowing down the progression of the disease for some, but often don't work at all for others, sometimes making them feel even worse.
Eisai is the manufacturer of Aricept, which is one of the few drugs currently on the market that can help slow early memory decline, but which is effective for only six to nine months.
Corium had previously reported "positive" PK bioequivalence data comparing once-weekly Corplex Donepezil and daily oral Aricept at steady state.